S423
Clinical - Gynaecological
ESTRO 2026
(95%CI:69.5–99.3) and 5-year OS 94.4% (95%CI:66.6–99.2) for this group.
Conclusion: We report outcomes in patients with more advanced disease than in EMBRACE-I(2), with comparable OS for our higher-risk population and improved 5-year OS over real-world EMBRACE-II data(3). IC did not compromise radiotherapy delivery, with higher chemotherapy compliance and superior OTT times versus international real-world data. Half our population had no measurable tumour at BT, correlating with excellent outcomes and supporting its use as a surrogate of treatment response.Our findings support the role of IC in LACC, including in those with more advanced disease than initially included in INTERLACE. References:
45 BT tumour measurements were available; no measurable tumour seen in 23 (51.1%). Median-OTT was 40 days (range 37–51); all completed radiotherapy, 1 receiving stereotactic boost instead of BT. 37 (71.1%) received 50.4Gy/28fractions, 15 (28.9%) 45Gy/25fractions for external beam treatment, 38 (73.1%) receiving intensity- modulated radiotherapy. 19 (36.5%) received para-aortic radiotherapy. 22 (42.3%) received a simultaneous integrated nodal boost. 40 (76.9%) received MRI-image-guided BT. 12- week MRI response: complete 41 (78.8%), partial 7 (13.5%), stable 1 (1.9%), progressive 2 (3.8%), unavailable 2 (3.8%). 2- and 5-year PFS were 66.6% (95%CI:51.2–78.1) and 64.1% (95%CI:48.6–76.1). 2- and 5-year OS were 87.0% (95%CI:73.3–94.0) and 74.6% (95%CI:58.7–85.2) (figure 1). Of 23 patients with no measurable tumour at BT, 1 relapsed at 10.2months, 5-year PFS 95.0%
1 - McCormack M, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard
chemoradiotherapy alone in patients with locally advanced cervical cancer. The Lancet. 2024 Oct;404(10462):1525–35.2 - Pötter R, et al. MRI-guided adaptive brachytherapy in
Made with FlippingBook - Share PDF online